Pharma researchers are tasked with organizing disparate data, which detracts from time spent understanding disease mechanisms and enabling the development of more effective drugs. Paradigm4 is tackling this issue with a new platform based on a novel approach to data organization and elastic computing. Even companies with small budgets can access this amazing computational power at a very cost-effective price. — Marilyn Matz and Zach Pitluk, Ph.D.
Addressing the vital economic challenge of uncovering new critical quality attributes (CQAs), Paradigm4’s REVEALTM Analytical Development app enables data analysts…
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns
